Principal Financial Group Inc. raised its stake in MetLife, Inc. (NYSE:MET - Free Report) by 2.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 677,596 shares of the financial services provider's stock after acquiring an additional 18,341 shares during the period. Principal Financial Group Inc. owned 0.10% of MetLife worth $54,404,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in MetLife by 33.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,663,239 shares of the financial services provider's stock worth $2,019,427,000 after purchasing an additional 6,213,923 shares in the last quarter. Geode Capital Management LLC grew its position in MetLife by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 11,931,536 shares of the financial services provider's stock worth $973,901,000 after buying an additional 158,107 shares during the last quarter. Norges Bank acquired a new position in MetLife in the fourth quarter worth approximately $730,716,000. Northern Trust Corp grew its position in MetLife by 15.7% in the fourth quarter. Northern Trust Corp now owns 7,052,202 shares of the financial services provider's stock worth $577,434,000 after buying an additional 958,458 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in MetLife by 4.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 6,434,737 shares of the financial services provider's stock worth $526,869,000 after buying an additional 290,734 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.
MetLife Stock Performance
Shares of MetLife stock traded up $0.55 during trading on Tuesday, hitting $79.73. 247,503 shares of the stock were exchanged, compared to its average volume of 3,434,563. The stock has a market capitalization of $53.53 billion, a price-to-earnings ratio of 12.96, a price-to-earnings-growth ratio of 0.68 and a beta of 0.85. The company has a fifty day moving average price of $78.80 and a 200-day moving average price of $80.09. MetLife, Inc. has a 1-year low of $65.21 and a 1-year high of $89.05. The company has a current ratio of 0.16, a quick ratio of 0.16 and a debt-to-equity ratio of 0.55.
MetLife (NYSE:MET - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The financial services provider reported $1.96 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.00 by ($0.04). MetLife had a net margin of 6.08% and a return on equity of 20.89%. The business had revenue of $18.57 billion during the quarter, compared to the consensus estimate of $18.06 billion. During the same period in the prior year, the firm earned $1.83 EPS. The business's revenue for the quarter was up 15.6% on a year-over-year basis. As a group, equities analysts predict that MetLife, Inc. will post 9.65 EPS for the current fiscal year.
MetLife announced that its board has authorized a stock buyback program on Wednesday, April 30th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the financial services provider to repurchase up to 5.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its stock is undervalued.
MetLife Increases Dividend
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 6th were given a dividend of $0.5675 per share. This represents a $2.27 dividend on an annualized basis and a yield of 2.85%. This is a boost from MetLife's previous quarterly dividend of $0.55. The ex-dividend date was Tuesday, May 6th. MetLife's dividend payout ratio is currently 36.91%.
Analysts Set New Price Targets
Several research firms have weighed in on MET. Morgan Stanley lifted their price objective on shares of MetLife from $94.00 to $99.00 and gave the stock an "overweight" rating in a research report on Monday, May 19th. JPMorgan Chase & Co. cut their target price on shares of MetLife from $88.00 to $86.00 and set an "overweight" rating for the company in a research report on Wednesday, April 2nd. Barclays upped their price objective on shares of MetLife from $88.00 to $94.00 and gave the company an "overweight" rating in a research report on Monday. Wells Fargo & Company upped their price objective on shares of MetLife from $91.00 to $94.00 and gave the company an "overweight" rating in a research report on Tuesday, May 6th. Finally, Wall Street Zen lowered shares of MetLife from a "buy" rating to a "hold" rating in a research report on Saturday, May 24th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $94.67.
Get Our Latest Stock Report on MET
About MetLife
(
Free Report)
MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.
Read More

Before you consider MetLife, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.
While MetLife currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.